课题基金 / 基金详情

项目摘要

项目成果

MERIT E CUDKOWICZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although we do not fully know if disease study of cells in Petri dishes can fully emulate the developmental progression that occurs in human adult neurodegenerative disease like ALS, new described technical ability to generate Induced Pluripotent Cells (iPS) from ALS patients provides an exceptional tool by which we can explore these issues. Many recent insights into the pathophysiology of ALS come from the study of familial forms of this disease. The ability to actually have human cell lines- representing the natural disease in the most relevant cell types- motor neurons and astrocytes- will provide unprecedented tools to 1) study cell- cell interactions responsible for disease pathophysiology and 2) provide critical tools for drug discovery and genetic pathway analysis. Eventually these ALS cell lines will also be useful to compare common and uncommon pathways between ALS and other neurodegenerative iPS models. But - iPS cell biology is exceptionally new and we do not yet have sufficient information about the reliability of the cells generated, their ability to truly reflect human cell biology, recapitulate the protein, genetic and functional characteristics of native motor neurons and astroglia. Before we can embark on extensive use of these cells for basic/translational research- it would be critical to generate a series of cell lines- all produced under identical conditions, from different fALS mutations, to determine how representative they are for cell type specificity and functional biology. The overall proposal will involve four principal investigators, working in tight collaboration, to generate and evaluate familial ALS (fALS) iPS cell lines. Project 1, led by Dr. Eggan will obtain the skin biopsies from FALS and control patients, generate the fibroblast and ultimately the initial iPS lines. We will employ the aid of iZumi, a biotech company to be a central site for uniform protocol iPS cell generation. iPS cell lines with neural/glial characteristics will be sent to the Project 2 Lab- Motor neuron biology, lead by Chris Henderson and to Project 3 lab, Astrocytes- lead by Jeffrey Rothstein. These two projects/labs will determine which of the fALS iPS cell lines have the appropriate characteristics of motor neurons and astroglia, through a series of sequential analyses. Only those cell lines that meet final criteria (as compared to human ES cell and prior work on human astroglia) will then go on for final genetic analysis in the Project 4 lab, lead by Tom Maniatis. PUBLIC HEALTH RELEVANCE: Understanding the pathophysiology and development of new therapeutics for ALS has been an enormous challenge. The ability to actually have human cell lines- representing the natural disease in the most relevant cell types- motor neurons and astrocytes- will provide unprecedented tools to 1) study cell- cell interactions responsible for disease pathophysiology and 2) provide critical tools for drug discovery and genetic pathway analysis. Eventually these ALS cell lines will also be useful to compare common and uncommon pathways between ALS and other neurodegenerative iPS models. )
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.mcn.2013.07.007
发表时间: 2013-09
期刊: Molecular and cellular neurosciences
影响因子: --
作者: [Burkhardt MF, Martinez FJ, Wright S, Ramos C, Volfson D, Mason M, Garnes J, Dang V, Lievers J, Shoukat-Mumtaz U, Martinez R, Gai H, Blake R, Vaisberg E, Grskovic M, Johnson C, Irion S, Bright J, Cooper B, Nguyen L, Griswold-Prenner I, Javaherian A]
通讯作者: Javaherian A
DOI: 10.1371/journal.pone.0040154
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者: [Takazawa T, Croft GF, Amoroso MW, Studer L, Wichterle H, Macdermott AB]
通讯作者: Macdermott AB
Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)
  • 批准号:
    10741962
  • 项目类别:
  • 资助金额:
    $283.53万
  • 财政年份:
    2023
  • 负责人:
    MERIT E CUDKOWICZ
  • 依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
  • 批准号:
    10468050
  • 项目类别:
  • 资助金额:
    $239.4万
  • 财政年份:
    2011
  • 负责人:
    MERIT E CUDKOWICZ
  • 依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
  • 批准号:
    10213840
  • 项目类别:
  • 资助金额:
    $240.23万
  • 财政年份:
    2011
  • 负责人:
    MERIT E CUDKOWICZ
  • 依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
  • 批准号:
    8539105
  • 项目类别:
  • 资助金额:
    $274.22万
  • 财政年份:
    2011
  • 负责人:
    MERIT E CUDKOWICZ
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: